The goal of this clinical trial is to evaluate the feasibility of WGA-800CW with dedicated imaging systems for detection of invisible esophageal dysplasia in patients with Barrett's esophagus. The main questions it aims to answer are: * What is the optimal dose of WGA-800CW that maximizes the tumor-to-background ratio and enables clear visualization of the tumor? * Can fluorescence endoscopy with WGA-800CW in combination with qFME detect dysplastic esophageal lesions? In this non-randomized, non-blinded, prospective, feasibility intervention study, 49 participants with Barrett's esophagus will be included. Patients will undergo the combined procedure (qFME and/or OCT-NIRF and HD-WLE). WGA-800CW will be topically administered via a spray catheter during gastroscopy procedures and fluorescent signal will be assessed with qFME and/or OCT-NIRF.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Determine the optimal dose of WGA-800CW (study part A)
Timeframe: From enrollment to inclusion and data assessment of patient 9.
Determine the optimal dose of WGA-800CW (study part A)
Timeframe: From enrollment to inclusion and data assessment of patient 9.
Determine the optimal dose of WGA-800CW (study part A)
Timeframe: From enrollment to inclusion and data assessment of patient 9
Determine the feasibility for detection of dysplastic esophageal lesions with WGA-800CW intra-procedurally (study part B)
Timeframe: From enrollment till the last patient included.
Determine the optimal dose of WGA-800CW (study part A)
Timeframe: From enrollment to inclusion and data assessment of patient 9